Stem Cell-Based Therapies for Cancer

Bhere, Deepak; Shah, Khalid

doi:10.1016/bs.acr.2015.04.012

Cited by 13 publications

(7 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cell lines HepG2, huh7 and HUVEC were obtained from Chinese national human genome center (Shanghai, China). With regard to P53 status, HepG2 cells carry wild-type P53 and huh7 cells carry mutation P53 [ 34 ]. HepG2 cells were maintained in MEM and huh7 cells in DMEM containing 100U/ml of penicillin and 100 μg/ml of streptomycin in a humidified chamber at 37°C in 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer

Niu

Wang

et al. 2016

Aging

View full text Add to dashboard Cite

One important process in liver cancer growth and progression is angiogenesis. Vascular endothelial growth factor (VEGF) has the significant role in liver cancer angiogenesis. sFlt1 (soluble Fms-like tyrosine kinase-1) is the promising inhibitor of VEGF and can be used as the new method of inhibiting angiogenesis. MSCs (Mesenchymal stem cells) can infiltrate into tumor tissue and function as the efficient transgene delivery mediator. Here, we engineered murine MSCs to express sFlt1 and examined the anti-tumor effect of MSC- sFlt1 in combination with continues low-dose doxorubicin treatment. We found that this combination therapy significantly inhibited liver cancer cells proliferation. Above all, HepG2 xenografts treated with this combination therapy went into remission. It is of note that this inhibition effect was not p53 binding and by increasing caspase8. This study suggests that this combination treatment has novel therapeutic potential for liver cancer because of significantly inhibiting cancer cells growth and anti-angiogenesis in vitro and in vivo.

show abstract

Section: Methodsmentioning

confidence: 99%

Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer

Niu

Wang

et al. 2016

Aging

View full text Add to dashboard Cite

show abstract

“…Some examples include the expression of anti-cancer proteins (such as interleukins, pro-apoptotic proteins, etc. ), the production of pro-drugs activating enzymes, the delivery of oncolytic viruses and nanoparticles containing chemo-or radiotherapies (Bhere and Shah, 2015). Even though these treatments seem promising, we must consider that they can be toxic even to the MSC themselves and also that the MSC can enhance the tumor severity because of their angiogenic capacity, or they may even generate a new tumor elsewhere (Fiala, 1968;Blanton et al, 2009).…”

Section: Oncologymentioning

confidence: 99%

Adipose-derived mesenchymal stem/stromal cells: from the lab bench to the basic concepts for clinical translation

Frontini-López¹,

Gojanovich²,

Masone³

et al. 2018

Biocell

View full text Add to dashboard Cite

In the last years, much work has shown that the most effective repair system of the body is represented by stem cells, which are defined as undifferentiated precursors that own unlimited or prolonged self-renewal ability, which also have the potential to transform themselves into various cell types through differentiation.All tissues that form the body contain many different types of somatic cells, along with stem cells that are called 'mesenchymal stem (or stromal) cells' (MSC). In certain circumstances, some of these MSC migrate to injured tissues to replace dead cells or to undergo differentiation to repair it.The discovery of MSC has been an important step in regenerative medicine because of their high versatility. Moreover, the finding of a method to isolate MSC from adipose tissue, so called 'adipose-derived mesenchymal stem cells' (ASC), which share similar differentiation capabilities and isolation yield that is greater than other MSC, and less bioethical concerns compared to embryonic stem cells, have created self-praised publicity to procure almost any treatment with them. Here, we review the current techniques for isolation, culture and differentiation of human ASC (hASC), and describe them in detail. We also compile some advantages of the hASC over other stem cells, and provide some concepts that could help finding strategies to promote their therapeutic efficiency. BIOCELLISSN 1667-5746 (on-line) 2018 42 (3): [67][68][69][70][71][72][73][74][75][76][77]

show abstract

“…Although embryonic SCs possess tremendous potential for differentiation, their use has been restricted due to ethical issues, limited sources, and higher risk of malignant transformation compared to other types of SCs 46. Fortunately, various kinds of adult SCs have been studied extensively and used in clinical trials throughout the world 47. As of today, the sources of adult SCs include: 1) MSCs derived from bone marrow, human umbilical cord blood, and other tissues, which have been demonstrated to have neuroprotective effects, and may differentiate into other cell types, including neural cells; 2) CACs, which are bone marrow-derived, and provide primarily paracrine support to the vasculature to foster vessel repair; 3) ECFCs, which are isolated from peripheral blood, cord blood, or the stromal vascular fraction, and can form endothelial cells; 4) neural precursor cells, which are multipotent cells found in the developing as well as the adult central nervous system and are heterogeneous, self-renewing, and mitotically active; and 5) induced pluripotent SCs, which can be generated from somatic cells after being treated with a defined cocktail of transcription factors, but tend to be time-consuming and costly 47,48…”

Section: Cell-based Therapy: the Next Generation Of Rop Treatment?mentioning

confidence: 99%

“…Research has aimed to use a variety of SC types to study drug delivery or gene therapy 47. In a 5-year follow-up study of femoral osteonecrosis in patients with sickle-cell disease, implantation of autologous bone marrow-derived mononuclear cells was reported to relieve pain significantly and slow the progressive early stages of femoral osteonecrosis.…”

Section: Cell-based Therapy: the Next Generation Of Rop Treatment?mentioning

confidence: 99%

Promoting vascular repair in the retina: can stem/progenitor cells help?

Trinh¹,

Calzi²,

Shaw³

et al. 2016

View full text Add to dashboard Cite

Since its first epidemic in the 1940s, retinopathy of prematurity (ROP) has been a challenging illness in neonatology. Higher than physiological oxygen levels impede the development of the immature retinal neuropil and vasculature. Current treatment regimens include cryotherapy, laser photocoagulation, and anti-VEGF agents. Unfortunately, none of these approaches can rescue the normal retinal vasculature, and each has significant safety concerns. The limitations of these approaches have led to new efforts to understand the pathological characteristics in each phase of ROP and to find a safer and more effective therapeutic approach. In the era of stem cell biology and with the need for new treatments for ROP, this review discusses the possible future use of unique populations of proangiogenic cells for therapeutic revascularization of the preterm retina.

show abstract

Stem Cell-Based Therapies for Cancer

Cited by 13 publications

References 140 publications

Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer

Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer

Adipose-derived mesenchymal stem/stromal cells: from the lab bench to the basic concepts for clinical translation

Promoting vascular repair in the retina: can stem/progenitor cells help?

Contact Info

Product

Resources

About